story of the week
Alpelisib Plus Fulvestrant for PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1
Ann. Oncol 2020 Nov 24;[EPub Ahead of Print], F André, EM Ciruelos, D Juric, S Loibl, M Campone, IA Mayer, G Rubovszky, T Yamashita, B Kaufman, YS Lu, K Inoue, Z Pápai, M Takahashi, F Ghaznawi, D Mills, M Kaper, M Miller, PF Conte, H Iwata, HS RugoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.